| Title |
Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases
|
|---|---|
| Published in |
Biologics in Therapy, May 2012
|
| DOI | 10.1007/s13554-012-0003-4 |
| Pubmed ID | |
| Authors |
Raafay Sophie, Abeer Akhtar, Yasir J. Sepah, Mohamed Ibrahim, Millena Bittencourt, Diana V. Do, Quan Dong Nguyen |
| Abstract |
In the western hemisphere, age-related macular degeneration (AMD) is the leading cause of visual loss in the elderly. Currently approved therapies for AMD include argon laser, photodynamic therapy, and antivascular endothelial growth factor (VEGF) therapy. The index review discusses aflibercept (VEGF Trap-Eye) in the context of current anti-VEGF therapies for neovascular AMD and other retinal vascular diseases. It highlights important differences between VEGF Trap-Eye and currently used anti-VEGF therapies for neovascular AMD; and discusses the efficacy of these treatments utilizing information from landmark clinical trials. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 53 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 26% |
| Student > Master | 8 | 15% |
| Student > Doctoral Student | 5 | 9% |
| Student > Ph. D. Student | 5 | 9% |
| Student > Postgraduate | 4 | 8% |
| Other | 9 | 17% |
| Unknown | 8 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 32% |
| Biochemistry, Genetics and Molecular Biology | 7 | 13% |
| Agricultural and Biological Sciences | 7 | 13% |
| Engineering | 3 | 6% |
| Social Sciences | 2 | 4% |
| Other | 7 | 13% |
| Unknown | 10 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 December 2022.
All research outputs
#4,705,809
of 25,371,288 outputs
Outputs from Biologics in Therapy
#2
of 20 outputs
Outputs of similar age
#30,978
of 178,785 outputs
Outputs of similar age from Biologics in Therapy
#1
of 2 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 20 research outputs from this source. They receive a mean Attention Score of 2.6. This one scored the same or higher as 18 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 178,785 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them